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Background: Malaria caused by Plasmodium falciparum infects roughly 30,000 individuals in Haiti each year. Haiti
has used chloroquine (CQ) as a first-line treatment for malaria for many years and as a result there are concerns
that malaria parasites may develop resistance to CQ over time. Therefore it is important to prepare for alternative
malaria treatment options should CQ resistance develop. In many other malaria-endemic regions, antifolates,
particularly pyrimethamine (PYR) and sulphadoxine (SDX) treatment combination (SP), have been used as an
alternative when CQ resistance has developed. This study evaluated mutations in the dihydrofolate reductase (dhfr)
and dihydropteroate synthetase (dhps) genes that confer PYR and SDX resistance, respectively, in P. falciparum to
provide baseline data in Haiti. This study is the first comprehensive study to examine PYR and SDX resistance
genotypes in P. falciparum in Haiti.
Methods: DNA was extracted from dried blood spots and genotyped for PYR and SDX resistance mutations in P.
falciparum using PCR and DNA sequencing methods. Sixty-one samples were genotyped for PYR resistance in
codons 51, 59, 108 and 164 of the dhfr gene and 58 samples were genotyped for SDX resistance codons 436, 437,
540 of the dhps gene in P. falciparum.
Results: Thirty-three percent (20/61) of the samples carried a mutation at codon 108 (S108N) of the dhfr gene. No
mutations in dhfr at codons 51, 59, 164 were observed in any of the samples. In addition, no mutations were
observed in dhps at the three codons (436, 437, 540) examined. No significant difference was observed between
samples collected in urban vs rural sites (Welch’s T-test p-value = 0.53 and permutations p-value = 0.59).
Conclusion: This study has shown the presence of the S108N mutation in P. falciparum that confers low-level PYR
resistance in Haiti. However, the absence of SDX resistance mutations suggests that SP resistance may not be
present in Haiti. These results have important implications for ongoing discussions on alternative malaria treatment
options in Haiti.
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Malaria causes almost half a million deaths worldwide
every year, with Plasmodium falciparum accounting for
most of the deaths [1]. In Haiti, roughly 30,000 people
contract malaria annually [2], making it a significant
public health concern for the country. The treatment for
malaria in Haiti has relied on chloroquine (CQ) for sev-
eral decades [3,4]. However, there is evidence that CQ-
resistance genotypes may be emerging in Haiti [5,6] and
there are ongoing discussions about the need to incorp-
orate alternative treatments for the management of
malaria.
Many malaria endemic countries that reported CQ re-
sistance switched to antifolate treatments, especially the
combination treatment of pyrimethamine (PYR) and sul-
phadoxine (SDX) [7]. In Haiti, PYR was first introduced in
the early 1960s during the global effort to eliminate mal-
aria [3]. The Haiti Ministry of Health, in partnership with
the World Health Organization, worked to reduce malaria
in Haiti by incorporating PYR in addition to CQ which
was already being used [3] and insecticide spraying to kill
mosquitoes. After a decade of use, PYR-resistant strains of
P. falciparum were reported in Haiti based on in vitro
studies [8], but no SP resistance was observed in vivo [8].
Since 1985, there have been no additional comprehensive
studies to examine SP resistance in Haiti [9].
The in vitro and in vivo resistance of P. falciparum to
PYR and SDX has been associated with single point
mutations in the dihydrofolate reductase (dhfr) [10-12]
and dihydropteroate synthase (dhps) genes [13-15], re-
spectively. These same point mutations have also been
associated with SP resistances. Correlations have been
found between SP resistance and point mutations at dhfr
codons 51, 59, 108, and 164 and dhps codons 436, 437,
and 540 [16-20]. The mutation at codon 108 in dhfr is
the first to develop in a population under pressure from
PYR use [21,22]. The stepwise evolution of additional
mutations, particularly at codons 51 and 59, directly cor-
relates with increased resistance to PYR [10,12,23,24]. To
date, no comprehensive molecular studies on dhfr and
dhps genotypes associated with resistance to PYR and
SDX, respectively have been conducted in Haiti beyond a
single study that examined only three samples [25].
In this study, genetic markers for SP resistance in the
dhfr and dhps genes were assayed in P. falciparum sam-
ples from Haiti. The data obtained from this study are
important for future anti-malaria drug health policy dis-
cussions for Haiti and for understanding the evolution
of drug resistance in P. falciparum.
Methods
Study sites
The blood samples were collected from six sites: Terre
Noire in Port au Prince at the Blanchard Clinic (TN)and Leogane at the Hospital Sainte Croix (LN), Artibo-
nite (ART), Hinche (HN), Cap Haitien (CP), and Jacmel
(JM) (Figure 1). The TN community is very close to Port
au Prince international airport and, therefore, is categor-
ized as urban although the public health infrastructure is
very poor. LN, ART, HN, CP, and JM are located in rural
communities. The rural communities primarily engage
in subsistence farming and informal trade for income.
There is very limited electricity and piped water. Spring
water that feeds into seasonal rivers is a part of the land-
scape and a source for domestic water that contributes
to the growth of malaria-transmitting mosquitoes. There
is no active malaria control activity in the area.
Sample collection
Dried blood spots samples were obtained from 319 indi-
viduals. The samples were collected in Haiti between
May 2010 and February 2012. Table 1 includes a sum-
mary of the sample collection from each site. Two separ-
ate inclusion criteria were used for sample collection.
The first 196 samples were selected based on presenta-
tion of malaria-like symptoms (Sample Set 1) and were
collected only from TN. The other 123 samples (Sample
Set 2) were included based on positive P. falciparum de-
tection using microscopy and included samples from TN
(n= 36), LN (n = 31), ART (n = 25), HN (n = 10), CP
(n = 10), and JM (n = 11). All malaria-infected patients
were treated according to the standard policy available
at the clinics. The study was approved by the Haiti Eth-
ical Review Board, UF-IRB, and the Office of Research
Protections, US Army Medical Research and Materiel
Command (USAMRMC).
DNA extraction
DNA was extracted from dried blood spots using a metha-
nol wash protocol as previously described [26]. Two
1.2 mm punches were taken from each dried blood spot
sample and placed in 0.2 ml tubes. The punches were
soaked in methanol at room temperature for 15 min. The
methanol was then removed and the punches air-dried for
about 30 min. Sterile DNA grade water (65 ul) was then
added to each tube and the tubes were heated to 97°C for
15 min.
PCR amplification
To detect the presence of P. falciparum DNA in the
samples, the small subunit ribosomal RNA (ssu rRNA)
gene of P. falciparum was amplified as described in Lon-
dono et al. [5]. Subsequent amplification and genotyping
of dhfr and dhps was conducted on all Set 1 samples
with positive ssu rRNA results and all Set 2 samples.
Regions of the dhfr (522 bp) and dhps (438 bp) genes
were amplified using a nested PCR protocol as previ-
ously described [27] except that the amplicons were
Figure 1 Map of sample collection sites (red stars) in Haiti.
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mer sequences for each nested step and the nucleotide
location are listed in Table 2. All PCR reactions included
reagents at the following concentrations: 1X GoTaq Flexi
Buffer, 0.75 mM MgCl2, 0.2 mM each nucleotide,
0.25 μM for each primer, and 1.25 U of Go Taq Hot Start
Polymerase (Promega, Madison, WI). The temperature
protocol used for all primary PCRs (PCR 1) was asTable 1 Sampling summary
Study Site Classification No. of samples tested




Cap Haitien Rural 10
Jacmel Rural 11
Total – 319follows: initial denaturation at 94°C for 3 min, 40 cycles
of denaturation at 94°C for 1 min, annealing at 45°C for
2 min, extension at 72°C for 2 min, and a final extension
at 72°C for 10 min. The temperature protocol used for
the nested PCRs (PCR 2) was as follows: initial denatur-
ation at 94°C for 3 min, 40 cycles of denaturation at 94°C
for 1 min, annealing at 50°C for 2 min, extension at 72°C











Table 2 Primer sequences used for nested PCR protocol and sequencing
Gene Primer Sequence { Nucleotide location
dhfr PCR1 M1* TTTATGATGGAACAAGTCTGC −3 to 18
M5* AGTATATACATCGCTAACAGA 625 to 645
PCR2 M3* TTTATGATGGAACAAGTCTGCGACGTT −3 to 24
F/* AAATTCTTGATAAACAACGGAACCTTTTA 491 to 519
dhps PCR1 R2* AACCTAAACGTGCTGTTCAA 223 to 242
R/* AATTGTGTGATTTGTCCACAA 913 to 933
PCR2 K* TGCTAGTGTTATAGATATAGGATGAGCATC 269 to 298
K/* CTATAACGAGGTATTGCATTTAATGCAAGAA 676 to 706
Seq Kb† ATTGGTTTCGCATCACATTT 408 to 427
{Primer sequences listed as forward primer first followed by reverse primer. All primers listed 5’ to 3’.
*Primers taken from Duraisingh et al. [27].
†Primer designed for nested sequencing of dhps codon 436 and 437.
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PCR products were Sanger sequenced at the University of
Florida’s Interdisciplinary Center for Biotechnology Re-
search DNA Sequencing Core Laboratory with BigDyeTM
chemistry (Applied Biosystems, Foster City, CA) on an
Applied Biosystems 3730 Genetic Analyzer. The PCR 2
forward and reverse primers were used for sequencing
the dhfr and dhps PCR amplicons. An additional primer
(Kb, see Table 2 for primer sequence) was designed for
nested sequencing of dhps amplicons that gave poor
sequences with the PCR 2 primers for the region includ-
ing codons 436 and 437. Sequence data were aligned to
P. falciparum 3D7 sequences [GenBank: XM_001351443
and XM_001349382] using Sequencher 4.10.1. (Gene
Codes Corp). The dhfr and dhps gene sequences were
scanned for previously identified dhfr and dhps point
mutations in resistance-associated codons (see Table 3).
Statistical analysis
Welch’s t-test and permutations were used to determine
if there was a significant difference in the number of
samples with detectable levels of P. falciparum DNA
(ie, positive PCR results with ssu rRNA, dfhr, or dhps)
between Sample Set 1 and Sample Set 2. Additionally,
the proportion of samples that carried each resistance-Table 3 List of wild type and resistance codon sequences




dhfr 51 AAT, AAC (N) ATT (I)
59 TGT (C) CGT (R)
108 AGC (S) AAC (N), ACC (T)
164 ATA(I) TTA (L)
dhps 436 TCT (S) GCT (A), TTT (F)
437 GCT (A) GGT (G)
540 AAA (K) GAA (E)associated mutation was determined. Welch’s t-test and
permutations were used to compare the proportion of
samples with mutations between samples collected in
an urban region (TN) to samples collected in a rural
region (LN, CP, HN, and JM). All statistical analysis
were completed using the open source software package
R version 2.14.1 [28].
Results
Sampling summary and positive amplification results
A total of 319 samples were collected in this study. Sam-
ple Set 1 included 196 samples and Sample Set 2
included 123 samples (see Table 1). A summary of amp-
lification results for the three genes is presented in
Table 4. The proportion of samples with detectable
levels of P. falciparum DNA (i e, positive amplification
of ssu rRNA, dhfr, or dhps) was compared between Sam-
ple Set 1 and Sample Set 2 for the TN site. The propor-
tions (Sample Set 1 = 0.07 and Sample Set 2 = 0.72) were
determined to be significantly different as assessed by
Welch’s T-test and permutation (p-value < < 0.001).
The dhfr and dhps genes were amplified in Set 1 sam-
ples with positive ssu rRNA results and Set 2 samples.
Of these samples, 65 were successfully PCR amplified
for the dhfr gene and 61 samples were successfully
sequenced [Genbank: JX217825 – JX217828]. Likewise,
the dhps gene was successfully amplified in 73 samples
and 58 samples were successfully sequenced. Finally,
complete and matched dhfr and dhps sequence data
were available for 46 samples.
Dhfr and dhps mutations
Of the 61 samples that were successfully sequenced for
dhfr, 20 samples (32.79%) carried the S108N mutation
(Table 5) [Genbank: JX217825]. Wild type alleles were
observed in all samples at dhfr codons 51, 59, and 164
(Table 5). Other studies have reported two possible wild
Table 4 Amplification and sequencing results
Study Site Total
samples
# Positive amplifications # Sequenced
ssu rRNA dhfr dhps dhfr dhps Both dhfr and dhps




31 (SS1 = 10,
SS2 = 21)
30 (SS1 = 12,
SS2 = 18)
23 (SS1 = 10,
SS2 = 13)
21 (SS1 = 10,
SS2 = 11)
Leogane 31 24 14 18 13 13 10
Hinche 10 6 5 8 5 8 4
Cap Haitien 10 1 4 8 4 7 4
Jacmel 11 6 9 8 9 7 7
Total* 294 76 65 73 61 58 46
†Includes the number of samples for samples set (SS) in parentheses; SS1 = Sample Set 1 and SS2= Sample Set 2.
*Total does not include Artibonite samples. None of the Artibonite samples contained positive amplifications for ssu rRNA, dhfr, or dhps.
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coding for asparagine, (N) (Table 3), but only the AAT
allele was observed in this study’s samples. In addition to
the S108N mutation, a mutation was observed in codon
62 in a single sample that resulted in an amino acid
change from threonine, (T) to leucine, (L) [Genbank:
JX217827]. Another mutation was observed in codon
158 of two samples that resulted in an amino change
from aspartic acid to glycine [Genbank: JX217825]. No
mutations were observed in the dhps gene in the
samples.Urban and rural S108N frequency comparison
Of the 61 samples that were successfully sequenced for
dhfr, 30 samples were collected from an urban site (TN)
and 31 were collected from rural sites (LN, HN, CP, and
JM). The proportion of samples with the S108N muta-
tion in each study site is represented in Figure 2. Eleven
(36.67%) of the samples collected from the urban site
and nine (29.03%) from the rural sites had the S108N
mutation. The proportion of samples with the S108N
mutation did not differ significantly between the samples
collected in urban vs rural sites, based on Welch’s T-test
(p-value = 0.53) and permutations (p-value = 0.59), sug-
gesting that that samples collected from the urban site
are not significantly more likely to carry the S108N mu-
tation than the samples from the rural site.Table 5 Percent of samples with S108N mutation for each
collection site
Study Site # DHFR sequenced S108N mutants (%)
Terre Noire 30 11 (36.67%)
Leogane 13 2 (13.33%)
Hinche 5 0 (0%)
Cap Haitien 4 1 (25%)
Jacmel 9 6 (66.67%)
Total 61 20 (32.79%)Discussion
Sampling summary and presence of Plasmodium
falciparum DNA
The purpose of the present study was to investigate the
presence of SP resistance associated mutations in the
dhfr and dhps genes in P. falciparum in Haiti. As
reported in Table 1, a total of 319 samples were col-
lected. However, only 76 samples, or 24%, had positive
ssu rRNA amplification. An additional 16 samples from
Set 2 amplified dhfr or dhps, although they did not suc-
cessfully amplify ssu rRNA. Furthermore, there was a
significant disparity in the number of samples with de-
tectable levels of P. falciparum DNA (i e, positive ampli-
fication for ssu rRNA, dhfr, or dhps) between the
samples that were collected based on malaria-like symp-
toms (Sample Set 1) and microscopy (Sample Set 2)
from TN (p-value < <0.001). It is likely that malaria is
often over-diagnosed in Haiti as the symptoms of mal-
aria (fever, chills, fatigue, etc.) are similar to that of other
diseases, thus the samples from Set 1 were less likely to
contain P. falciparum DNA.
PYR-resistance mutations
Sixty-one samples were sequenced successfully for dhfr
and 20 of these samples carried the S108N dhfr muta-
tion associated with PYR resistance. No other resistance
mutations genotyped in the dhfr gene were observed.
Previous studies have reported that the S108N mutation
is essential to PYR resistance [10,11,29] and is the first
mutation seen as PYR resistance develops [21,22]. The
single S108N mutation is associated with a lower level of
resistance to PYR relative to multi-allelic resistance asso-
ciated with S108N plus other mutations at codon posi-
tions 51, 59, and 164 [10,12,23,24]. Therefore, these
results suggest that there may be PYR resistance in Haiti
and that the resistance would be low based on the ab-
sence of multiple mutations at codons 51, 59, and 164 in
the P. falciparum samples analysed.
Continued presence of PYR-resistant S108N-only
haplotypes in Haiti decades after PYR use was
Figure 2 Comparison of the prevalence of S108N mutation by collection site.
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single S108N haplotype was observed, while in other
studies the S108N mutation is rarely observed alone.
Recent studies of discontinued use of SP in Peru, fol-
lowed up to five years, have noted a decrease in mul-
tiple mutation dhfr haplotypes while noting an
increase in S108N only haplotypes [30,31]. This may
be due to a greater fitness cost for multiple mutation
haplotypes in the absence of antifolate drug pressure
[31]. However, no studies have documented a complete
loss of S108N haplotypes following discontinued use of
SP; thus, it is not possible to calculate how quickly
S108N may be lost. Furthermore, studies have not
found evidence of strong selective pressure on the
S108N-only haplotype [32] suggesting that there may
be minimal fitness costs associated with maintaining
only the S108N allele. Another possible explanation for
the presence of a PYR-resistant mutation in Haiti is
that privately run clinics funded by charities and un-
regulated donations of medications may be using SP
regimes for the clinical management of malaria in
Haiti. There is no evidence that this is happening but
the lack of government oversight of private clinics run
by charities may lead to unauthorized medications
being used. There is also the possibility of cross-
resistance due to sulphonamide-based treatments for
HIV that act on the folate pathway and may induce
mutations in P. falciparum dhfr gene [33]. Iyer et al.
found that P. falciparum strains with the S108N muta-
tion were resistant to the sulphadmide-based HIV
treatment trimethoprim [33], suggesting that wide-
spread use of trimethoprim could result in selection ofresistance mutations in the dhfr. Another possibility is
that the S108N mutation may have been introduced
from South American countries, such as Bolivia,
Columbia, or Peru where PYR or SP has been used or
is being used. For example, a study in Peru reported a
79% prevalence of the single S108N haplotype [31].
Corredor et al. also reported an increase in the single
S108N haplotypes to 26% in the Amazon basin in Co-
lombia [34]. Few studies have examined the presence
of dhfr resistance haplotypes in Central America, with
the exception of Jovel et al. [35] (Honduras) and
Samudio et al. [36] (Panama). Neither of these studies
observed the single S108N haplotype in their samples.
Investigations into the origin of the dhfr S108N muta-
tion in Haiti could provide insight into how drug re-
sistance mutations arise and spread throughout a
population.
Two additional mutations in the dhfr (T62L and
D148G) that have not previously been reported were
observed in this study. Both mutations result in a change
in side-chain polarity of the amino acid (polar to non-
polar) and the D148G mutation results in a change of
side-chain charge, suggesting that these mutations may
affect P. falciparum functionality. Further studies are
needed to investigate whether these mutations affect re-
sistance to PYR.
SDX resistance mutations
The lack of mutations in the dhps genes in the samples
suggests that no drug pressure has been acting upon the
gene. Further studies are recommended to increase the
sample size and sampling sites and to conduct in vitro
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Haiti. Nonetheless, based on the data in this paper, the
lack of mutations in the dhps may indicate that P. falcip-
arum parasites in Haiti are still sensitive to SDX.
Conclusion
The finding of the dhfr S108N mutation would suggest
that PYR-resistant P. falciparum may still be present in
Haiti, at least at a low level. However, S108N alone has
not been associated with SP resistance and, thus, the use
of combination SP for the treatment of malaria in Haiti
should be considered as a replacement medication in the
event that CQ resistance emerges.
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